company background image
2181

Mabpharm SEHK:2181 Stock Report

Last Price

HK$0.35

Market Cap

HK$1.4b

7D

-2.8%

1Y

-63.2%

Updated

05 Oct, 2022

Data

Company Financials
2181 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

2181 Stock Overview

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China.

Mabpharm Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mabpharm
Historical stock prices
Current Share PriceHK$0.35
52 Week HighHK$1.20
52 Week LowHK$0.34
Beta0.51
1 Month Change-30.00%
3 Month Change-50.70%
1 Year Change-63.16%
3 Year Change-61.11%
5 Year Changen/a
Change since IPO-71.07%

Recent News & Updates

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

2181HK BiotechsHK Market
7D-2.8%4.1%2.9%
1Y-63.2%-55.2%-24.9%

Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned -58.8% over the past year.

Return vs Market: 2181 underperformed the Hong Kong Market which returned -28.6% over the past year.

Price Volatility

Is 2181's price volatile compared to industry and market?
2181 volatility
2181 Average Weekly Movement12.5%
Biotechs Industry Average Movement8.3%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.8%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2181 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: 2181's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2018413Hao Wanghttps://www.mabpharm.cn

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer.

Mabpharm Limited Fundamentals Summary

How do Mabpharm's earnings and revenue compare to its market cap?
2181 fundamental statistics
Market CapHK$1.44b
Earnings (TTM)-HK$290.64m
Revenue (TTM)HK$33.64m

42.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2181 income statement (TTM)
RevenueCN¥30.48m
Cost of RevenueCN¥11.06m
Gross ProfitCN¥19.42m
Other ExpensesCN¥282.81m
Earnings-CN¥263.39m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.064
Gross Margin63.71%
Net Profit Margin-864.06%
Debt/Equity Ratio16.6%

How did 2181 perform over the long term?

See historical performance and comparison